KR950016723A - 자가면역 질병의 억제 방법 - Google Patents

자가면역 질병의 억제 방법 Download PDF

Info

Publication number
KR950016723A
KR950016723A KR1019940034914A KR19940034914A KR950016723A KR 950016723 A KR950016723 A KR 950016723A KR 1019940034914 A KR1019940034914 A KR 1019940034914A KR 19940034914 A KR19940034914 A KR 19940034914A KR 950016723 A KR950016723 A KR 950016723A
Authority
KR
South Korea
Prior art keywords
compound
autoimmune diseases
formula
suppress autoimmune
pyrrolidino
Prior art date
Application number
KR1019940034914A
Other languages
English (en)
Inventor
해롤드 주커만 스티븐
Original Assignee
피터 지. 스트링거
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 피터 지. 스트링거, 일라이 릴리 앤드 캄파니 filed Critical 피터 지. 스트링거
Publication of KR950016723A publication Critical patent/KR950016723A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)

Abstract

자가면역 질병의 억제가 필요한 인간에게 유효량의 하기 일반식(I)의 화합물 또는 그의 약학적으로 허용가능한 염 또는 용매화물을 투여함을 포함하는, 자가면역 질병의 억제 방법을 개시한다.
상기식에서,
R1및 R3는 독립적으로 수소, -CH3,(여기에서, Ar은 임의로 치환된 페닐이다)이고; R2는 피롤리디노 및 피페리디노로 이루어진 그룹중에서 선택된다.

Description

자가면역 질병의 억제 방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (4)

  1. 자가면역 질병의 억제에 사웅하기 위한 하기 일반식(I)의 화합물 또는 그의 약학적으로 허용가능한 염 또는 용매화물:
    상기식에서,
    R1및 R3는 독립적으로 수소, -CH3,(여기에서, Ar은 임의로 치환된 페닐이다)이고; R2는 피롤리디노 및 피페리디노로 이루어진 그룹중에서 선택된다.
  2. 제1항에 있어서, 염산염인 화합물.
  3. 제1항에 있어서, 예방학적으로 투여되는 화합물.
  4. 제1항에 있어서, 하기 구조식을 갖는 화합물 또는 염산염:
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019940034914A 1993-12-21 1994-12-19 자가면역 질병의 억제 방법 KR950016723A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/170,608 US5521198A (en) 1993-12-21 1993-12-21 Methods of inhibiting autoimmune diseases
US08/170608 1993-12-31

Publications (1)

Publication Number Publication Date
KR950016723A true KR950016723A (ko) 1995-07-20

Family

ID=22620579

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940034914A KR950016723A (ko) 1993-12-21 1994-12-19 자가면역 질병의 억제 방법

Country Status (15)

Country Link
US (2) US5521198A (ko)
EP (1) EP0664123A1 (ko)
JP (1) JPH07215855A (ko)
KR (1) KR950016723A (ko)
CN (1) CN1108102A (ko)
AU (1) AU699255B2 (ko)
CA (1) CA2138509A1 (ko)
CZ (1) CZ320694A3 (ko)
HU (1) HUT71327A (ko)
IL (1) IL112031A (ko)
NO (1) NO944914L (ko)
NZ (1) NZ270164A (ko)
PH (1) PH31599A (ko)
RU (1) RU94044454A (ko)
ZA (1) ZA9410083B (ko)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5596106A (en) * 1994-07-15 1997-01-21 Eli Lilly And Company Cannabinoid receptor antagonists
US5434166A (en) * 1994-08-22 1995-07-18 Eli Lilly And Company Methods of inhibiting demyelinating and desmyelinating diseases
US5545641A (en) * 1994-10-20 1996-08-13 Eli Lilly And Company Methods of inhibiting physiological conditions associated with an excess of bradykinin
HUP9801829A3 (en) * 1995-02-06 1999-10-28 Lilly Co Eli Use of benzotiophene derivatives for producing pharmaceutical compositions for inhibiting effects of il-6
JPH11510479A (ja) 1995-06-07 1999-09-14 ネオルックス コーポレイション タモキシフェン類似体による心臓血管疾病の予防及び治療
IL120266A (en) 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
TW442286B (en) * 1996-02-28 2001-06-23 Pfizer New therapeutic uses of estrogen agonists
US5985932A (en) * 1996-02-28 1999-11-16 Pfizer Inc Inhibition of autoimmune diseases
US6117911A (en) * 1997-04-11 2000-09-12 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
US6008232A (en) * 1997-08-20 1999-12-28 Eli Lilly And Company Methods for preventing headaches
US6566560B2 (en) 1999-03-22 2003-05-20 Immugen Pharmaceuticals, Inc. Resorcinolic compounds
US6274635B1 (en) 1999-03-22 2001-08-14 Immugen Pharmaceuticals Inc. Alkylated resorcinol derivatives for the treatment of immune diseases
EP1175433B1 (en) 1999-05-04 2005-08-03 Strakan International Limited Androgen glycosides and androgenic activity thereof
AU2002213429A1 (en) * 2000-09-28 2002-04-08 Immugen Pharmaceuticals, Inc. Antiviral methods and compounds
WO2002026224A2 (en) * 2000-09-28 2002-04-04 Immugen Pharmaceuticals, Inc. Methods and compounds for inhibiting eicosanoid metabolism and platelet aggregation
AU2003214226A1 (en) * 2002-03-18 2003-10-08 Immugen Pharmaceuticals, Inc. Topical formulations of resorcinols and cannibinoids and methods of use
JP3887588B2 (ja) * 2002-08-30 2007-02-28 株式会社リガク Ｘ線回折による応力測定法
AU2004204675A1 (en) * 2003-01-06 2004-07-29 Wyeth The use of estrogen receptor alpha modulators for the treatment of multiphe sclerosis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US5075321A (en) * 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体
EP0776661A1 (en) * 1992-10-27 1997-06-04 Nippon Kayaku Kabushiki Kaisha Combined preparation of antiestrogen and glucocorticoid for the treatment of autoimmune disease
JP4111352B2 (ja) 1996-05-21 2008-07-02 新日鐵住金ステンレス株式会社 ステンレス鋼の高清浄化精錬法

Also Published As

Publication number Publication date
CZ320694A3 (en) 1995-09-13
CN1108102A (zh) 1995-09-13
AU8153794A (en) 1995-06-29
RU94044454A (ru) 1996-10-10
IL112031A (en) 1999-12-22
HUT71327A (en) 1995-11-28
EP0664123A1 (en) 1995-07-26
NO944914D0 (no) 1994-12-19
NZ270164A (en) 1997-08-22
JPH07215855A (ja) 1995-08-15
US6436958B1 (en) 2002-08-20
ZA9410083B (en) 1996-06-19
AU699255B2 (en) 1998-11-26
NO944914L (no) 1995-06-22
IL112031A0 (en) 1995-03-15
PH31599A (en) 1998-11-03
US5521198A (en) 1996-05-28
CA2138509A1 (en) 1995-06-22
HU9403658D0 (en) 1995-02-28

Similar Documents

Publication Publication Date Title
KR950016723A (ko) 자가면역 질병의 억제 방법
KR950016744A (ko) 트롬빈을 저해하는 방법
KR950016732A (ko) 피부 및 질의 위축 억제방법
KR950016738A (ko) 알쯔하이머 질병의 억제 방법
KR950016725A (ko) 폐 고혈압성 질병을 억제하는 방법
KR950016746A (ko) 비-펩티드 타키키닌 수용체 길항물질
KR950010893A (ko) 자궁내막증 억제 방법
KR970706818A (ko) 뉴로펩티드 y와 관련된 상태의 억제 방법(methods of inhibiting conditions associated with neuropeptide)
KR950010892A (ko) 자궁 섬유증 억제 방법
KR950016731A (ko) 지루 및 좌창의 억제 방법
KR950016745A (ko) 생리증상의 치료방법 및 이를 위한 조성물
KR950016726A (ko) 기능부전성 자궁 출혈을 억제하는 방법
KR950010890A (ko) 폐경기 증후군의 치료방법
KR950031069A (ko) 골손실의 억제 및 혈청 콜레스테롤의 강하 방법
KR950017957A (ko) 3, 4, 4-삼치환-피페리디닐-n-알킬카르복실레이트의 제법 및 중간체
KR950016730A (ko) 폐경기 후 증후군과 관련한 혈관 운동 증상 및 수반되는 심리학적 장애의 억제 방법
KR950010888A (ko) 평활근세포 증식 및 재발협착증을 억제하는 방법
KR950016737A (ko) 생리전 증후군/후기 황체 시기 불쾌성 질환 증상의 억제 방법
KR950016740A (ko) 조직의 불완전한 회복을 저해하는 방법
KR950010889A (ko) 혈관형성 및 혈관형성성 질병을 억제하는 방법
KR950016727A (ko) 트롬보모듈린 발현을 증가시키는 방법
KR950010887A (ko) 연골 퇴화 억제 방법
KR950010891A (ko) 내성 종양을 치료하는 방법
KR950016724A (ko) 폐경기 후 여성의 리비도를 증가시키는 방법
KR950016743A (ko) 마이엘로퍼옥시다제 활성을 억제하는 방법

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid